 NEW YORK, July 28, 2022 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th, 2022, on Thursday, August 4th, 2022, after the close of the US market. 